Japan boxing to adopt stricter safety rules after deaths of two fighters
Article content
The new measures were adopted during an emergency meeting of the Japan Pro Boxing Association (JPBA), the Japan Boxing Commission (JBC) and gym owners on Tuesday.
Article content
Article content
It was convened after super featherweight Shigetoshi Kotari and lightweight Hiromasa Urakawa, both 28, died days after brain surgery on injuries they sustained in separate bouts at Tokyo's Korakuen Hall on August 2.
Article content
The exact cause of the boxers' deaths is to be determined, but dehydration caused by cutting weight rapidly is regarded as a factor in making the brain more susceptible to bleeding, according to the World Boxing Association.
Article content
The deaths were 'really regrettable,' said JPBA president Shoji Kobayashi. 'We gathered today to establish a plan towards zero accidents.'
Article content
New measures to be implemented as soon as possible include urine tests for measuring dehydration and stricter rules on boxers' rapid weight loss, said Tsuyoshi Yasukochi, secretary-general of the JBC.
Article content
Ambulances will also be required on site, even for non-world championship bouts. They will partner with hospitals that are equipped to perform emergency surgery for head and other injuries.
Article content
Article content
There will also be new rules on how long before a fight sparring must be stopped during training, he said.
Article content
Officials decided 'to take all measures possible so we do not let the deaths of the two be in vain,' Yasukochi added.
Article content
Kotari collapsed and later died after going 12 rounds in an Oriental and Pacific Boxing Federation title fight. The JBC had already announced all future OPBF title bouts would be reduced to 10 rounds.
Article content
'That such an incident occurred involving top-level boxers means we may face arguments that boxing should be halted,' admitted Toshiharu Kayama, former Japan welterweight champion and president of the boxing gym Ebisu K's Box.
Article content
'We, the association and gyms, want to think and change' the way the sport is contested, Kayama said.
Article content
An accident investigation committee will work to find out the cause of the boxers' deaths later this month and guidance on prevention measures will be updated, Yasukochi said.
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
4 hours ago
- CTV News
Calgary bantamweight Jake (The One) Peacock returns to action in November in Tokyo
Canadian bantamweight Jake (The One) Peacock, is shown in this handout photo, in his Muay Thai bout against Japan's Shinji Suzuki at "One 171: Qatar" in the One Championship promotion, on Feb. 20, 2025. Peacock was born without a right hand. THE CANADIAN PRESS/Handout - One Championship (Mandatory Credit)
National Post
10 hours ago
- National Post
Top Japanese fighter retires to support comatose boxer brother
A Japanese boxer is retiring to support his brother who has been in a coma since a bout in May, as the sport in the country reels from the deaths of two fighters. Article content Former WBC strawweight champion Yudai Shigeoka's brother Ginjiro collapsed after a fight in Osaka three months ago and underwent emergency brain surgery. Article content Article content The 25-year-old remains in a coma but is no longer in a life-threatening condition, the Japan Boxing Commission says. Article content Ginjiro, a former IBF champion at the same weight who has a professional win-loss record of 11-2, was recently transferred to another hospital. Article content 'I encourage him every day, telling him not to give up and to do his best, so that the flame in his heart does not go out,' Yudai, 28, said in an Instagram post on Wednesday. Article content 'I believe it is my role as his older brother to enrich his life from now on.' Article content 'Plans are progressing steadily. That is why I have decided to retire. I have no regrets. The real challenge begins from here on out,' added Yudai, who has a 9-2 record. Article content Japanese boxing is under the spotlight after super featherweight Shigetoshi Kotari and lightweight Hiromasa Urakawa, both 28, died days after injuries they sustained in separate bouts in Tokyo on August 2. Article content Japanese boxing officials held an emergency meeting this week and vowed to introduce new safety rules. Article content New measures to be implemented as soon as possible include urine tests for measuring dehydration and stricter rules on boxers' rapid weight loss, said Tsuyoshi Yasukochi, secretary-general of the JBC. Article content
Globe and Mail
2 days ago
- Globe and Mail
Oncocytoma Market Poised for Growth Through 2032, Fueled by AI Diagnostics and Minimally Invasive Surgery
The Oncocytoma market is experiencing notable growth, with the 7MM projected to achieve a decent CAGR, according to DelveInsight's latest analysis. This growth reflects advancements in molecular diagnostics and minimally invasive surgical technologies that are reshaping treatment paradigms for this rare renal and salivary gland tumor. DelveInsight's report, ' Oncocytoma - Market Insight, Epidemiology And Market Forecast - 2032 ', provides a comprehensive assessment of oncocytoma market dynamics, disease epidemiology, and treatment advancements across the 7MM. The report forecasts that the oncocytoma market size in 7MM, which includes the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, is expected to increase notably over the coming years. This growth is primarily driven by the increased adoption of non-invasive treatment options and advancements in early detection technologies. The United States represents the largest share of the oncocytoma market. The EU4 countries and the United Kingdom collectively make up the second-largest market share. Download the oncocytoma market report to understand which factors are driving the oncocytoma therapeutic market @ Oncocytoma Market Trends. The epidemiological data presented in the report indicate key trends in incidence, demographics, and the oncocytoma patient pool. The data reveal a steadily expanding oncocytoma patient pool across the 7MM, with the median age at diagnosis for renal oncocytoma typically ranging from 62 to 68 years. Additionally, it has also been indicated that oncocytomas predominantly affect males across the studied regions. The report also explores the current and evolving Oncocytoma treatment landscape. As of now, there are no FDA-approved drugs specifically targeting oncocytoma. Instead, oncocytomas are typically managed through surgical excision (such as partial or radical nephrectomy) or minimally invasive techniques like cryoablation or radiofrequency ablation when necessary. While surgical intervention remains the cornerstone of current management, there is an accelerated innovation in diagnostic accuracy and the differentiation of these tumors from malignant renal counterparts. Recently, AI-driven diagnostic tools have been integrated into clinical practice, showing promising results in the diagnosis and preoperative planning for oncocytoma. One study revealed that an AI system achieved over 90% accuracy in distinguishing clear cell renal cell carcinoma (RCC) from oncocytoma using MRI scans. Additionally, a comparative analysis indicated that the AI model outperformed radiologists in distinguishing benign tumors, such as oncocytoma and angiomyolipoma, from RCC subtypes. This highlights the potential of AI to reduce diagnostic ambiguity within the oncocytoma treatment landscape. Discover evolving trends in the oncocytoma treatment landscape @ Oncocytoma Therapeutics Market. Looking ahead, the oncocytoma market is set for significant growth, driven by advancements in diagnostic technologies and surgical techniques. Despite challenges posed by the benign nature of these tumors, which can lead to misdiagnosis and potential overtreatment, the field is witnessing a paradigm shift. The integration of artificial intelligence in imaging and the development of molecular diagnostic tools are enhancing the accuracy of preoperative diagnosis, reshaping patient management strategies As research continues to uncover the molecular intricacies of oncocytomas, the market is expected to expand, offering more personalized treatment options and improved long-term monitoring techniques to address the unmet needs in this landscape. Unlock which oncocytoma drug is expected to capture the largest market share in 7MM by 2032. Visit the Oncocytoma Market Insights. Table of Contents 1. Key Insights 2. Executive Summary of Oncocytoma 3. Oncocytoma Competitive Intelligence Analysis 4. Oncocytoma: Market Overview at a Glance 5. Oncocytoma: Disease Background and Overview 6. Oncocytoma Patient Journey 7. Oncocytoma Epidemiology and Patient Population 8. Oncocytoma Treatment Algorithm, Current Treatment, and Medical Practices 9. Oncocytoma Unmet Needs 10. Key Endpoints of Oncocytoma Treatment 11. Oncocytoma Marketed Products 12. Oncocytoma Emerging Therapies 13. Oncocytoma: Seven Major Market Analysis 14. Attribute analysis 15. 7MM: Market Outlook 16. Oncocytoma Access and Reimbursement Overview 17. KOL Views 18. Oncocytoma Market Drivers 19. Oncocytoma Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer 23. About DelveInsight Related Reports Oncocytoma Pipeline Insight Oncocytoma Pipeline Insight provides comprehensive insights about the oncocytoma pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the oncocytoma companies. About DelveInsight DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
